Teva Furnishes Q3 2025 Financial Results, Increases 2025 Outlook for Austedo® and Non-GAAP EPS
Summary
Teva Pharmaceutical Industries Ltd. reported its Q3 2025 financial results on November 5, 2025, via Exhibit 99.1 press release, marking its 11th consecutive quarter of growth. Revenues reached $4.5 billion, a 3% YoY increase in U.S. dollars. Non-GAAP operating income margin improved to 28.9%, up 86 bps YoY. * Key Innovative brands revenue grew 33% YoY in LC to $830 million. * AUSTEDO® global revenues were $618 million. * The company increased its 2025 outlook for Austedo® and Non-GAAP EPS. * Teva is on track for a non-GAAP operating profit margin target of 30% by 2027.
Why It Matters
This update is material as Teva reported its 11th consecutive quarter of growth and increased its 2025 outlook for Austedo® and Non-GAAP EPS, signaling strong performance and positive future expectations driven by its innovative portfolio.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how TEVA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View TEVA Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000818686
- Filing Date
- Wednesday, November 5, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive